Marker Therapeutics, Inc.

Monthly Archives: June 2017

TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer

TapImmune has enrolled 50% (40/80) of the patients in its randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV 200 for treating triple-negative breast cancer (TNBC).
Read More

TapImmune Inc. Enters into Definitive Agreements to Raise $6.82 Million in a Private Placement from Accredited Investors and from the Exercise of Warrants by Existing Institutional Investors

TapImmune has entered into definitive subscription agreements to raise aggregate gross proceeds of approximately $6.82 million in a private placement transaction with accredited investors and from the exercise of certain outstanding Series E warrants by certain existing institutional investors.
Read More

TapImmune to Present at 2017 Biotechnology Innovation Organization International Convention

Dr. Glynn Wilson, Chairman and CEO of TapImmune, will present at the 2017 Biotechnology Innovation Organization International Convention held on June 19-22 in San Diego.
Read More

T-Cell Vaccine Maker TapImmune Looks To Monetize Expression Tech

TapImmune says it is exploring licensing out its nucleic acid-based protein expression technology PolyStart to vaccine developers.
Read More

Several Studies on Track for Ovarian and Breast Cancer Vaccine TPIV 200

Ovarian Cancer News Today has covered TapImmune's cancer vaccine for Ovarian and Breast Cancer, TPIV 200. Take a look.
Read More

TapImmune Tests Continue

The company is getting closer with several therapies under development, CEO Glynn Wilson said in a quarterly update last week.
Read More

TapImmune’s CEO Glynn Wilson on Q1 2017 Results – Earnings Call Transcript

Here is the complete transcript provided by Seeking Alpha from May 31st conference call and live webcast regarding 2017 first quarter clinical and corporate updates.
Read More